SALT
LAKE CITY, Aug. 8, 2024 /PRNewswire/ -- Sera
Prognostics Inc., The Pregnancy Company®
(NASDAQ: SERA), focused on improving maternal and neonatal health
by providing innovative pregnancy biomarker information to doctors
and patients, today announced that its management team will
participate in the following upcoming investor
conference:
UBS Genomic Medicine Summit, August
13-14. President and Chief Executive Officer, Zhenya Lindgardt, will participate in a panel
discussion: Future of Genetic Testing – Babies and
Beyond, on August 14 at
8:00 a.m. Pacific Time/11:00 a.m. Eastern Time.
Live audio of the webcast will be available online from the
Investors page of the Company's website at www.seraprognostics.com.
The webcast will be archived on the Investors page and will be
available for 90 days.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company
dedicated to improving the lives of women and babies through
precision pregnancy care. Sera's mission is to provide early,
pivotal pregnancy information to improve the health of mothers and
newborns, resulting in reductions in the costs of healthcare
delivery. Sera has a robust pipeline of innovative diagnostic tests
focused on the early prediction of preterm birth risk and other
complications of pregnancy. Sera's precision medicine
PreTRM® Test reports to a physician the individualized
risk of spontaneous premature delivery in a pregnancy, enabling
earlier proactive interventions in women with higher risk. Sera
Prognostics is headquartered in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation
and is the leading cause of illness and death in newborns. The 2023
March of Dimes Report Card shows that, for the last five
consecutive years, more than one in ten infants is born prematurely
in the United States.
Prematurity is associated with a significantly increased risk of
major long-term medical complications, including learning
disabilities, cerebral palsy, chronic respiratory illness,
intellectual disability, seizures, and vision and hearing loss, and
can generate significant costs throughout the lives of affected
children. The annual health care costs to manage short- and
long-term complications of prematurity in the United
States were estimated to be approximately $25
billion for 2016.
About the PreTRM® Test
The PreTRM® Test is the only broadly validated,
commercially available blood-based biomarker test that provides an
early, accurate and individualized risk prediction for spontaneous
preterm birth in asymptomatic singleton pregnancies. The PreTRM®
Test measures and analyzes proteins in the blood that are highly
predictive of preterm birth. The PreTRM® Test permits physicians to
identify, during the weeks 18 through 20 of pregnancy, which women
are at increased risk for preterm birth and its complications,
enabling more informed, personalized clinical decisions based on
each woman's individual risk. The PreTRM® Test is ordered by a
medical professional.
Sera Prognostics, the Sera Prognostics logo, The Pregnancy
Company, and PreTRM are trademarks or registered trademarks of Sera
Prognostics, Inc. in the United States and/or other
countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the Company's participation
in as well as the date, time and content of the Company's panel
discussion at the UBS conference; and the company's strategic
directives under the caption "About Sera Prognostics, Inc." These
"forward-looking statements" are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by
forward-looking statements. These risks and uncertainties include,
but are not limited to: net losses, cash generation, and the
potential need to raise more capital; revenues from the PreTRM Test
representing substantially all Company revenues to date; the need
for broad scientific and market acceptance of the PreTRM Test; a
concentrated number of material customers; our ability to introduce
new products; potential competition; our proprietary biobank;
critical suppliers; the COVID-19 pandemic and its potential
lingering impact on our operations, as well as the business or
operations of third parties with whom we conduct business;
estimates of total addressable market opportunity and forecasts of
market growth; potential third-party payer coverage and
reimbursement; new reimbursement methodologies applicable to the
PreTRM Test, including new CPT codes and payment rates for those
codes; changes in FDA regulation of laboratory-developed tests; the
intellectual property rights protecting our tests and market
position; and other factors discussed under the heading "Risk
Factors" contained in our Final Prospectus on Form S-1, which was
filed with the Securities and Exchange Commission on July 14,
2021, as well as any updates to those risk factors filed from time
to time in our Quarterly Reports on Form 10-Q, Annual Reports on
Form 10-K, or Current Reports on Form 8-K. All information in this
press release is as of the date of the release, and the Company
undertakes no duty to update this information unless required by
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-to-participate-in-panel-discussion-at-ubs-genomic-medicine-summit-on-august-14-2024-302217390.html
SOURCE Sera Prognostics, Inc.
